title: Pulmonary arterial hypertension during systemic lupus.
authors.forename: Gaël
authors.initials: G
authors.lastname: Cinquetti
authors.forename: Christelle
authors.initials: C
authors.lastname: Sordet
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Chatelus
authors.forename: Cécile
authors.initials: C
authors.lastname: Ronde-Oustau
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Javier
authors.forename: Jacques-Eric
authors.initials: JE
authors.lastname: Gottenberg
authors.forename: Jean
authors.initials: J
authors.lastname: Sibilia
mesh_terms: D000328:Adult; D000077300:Bosentan; D003520:Cyclophosphamide / Q000627:therapeutic use; D065627:Familial Primary Pulmonary Hypertension; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D013256:Steroids / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D013256:Steroids; D013449:Sulfonamides; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; D000077300:Bosentan